Results 211 to 220 of about 2,826,109 (303)

Potential for Carotenoid and Other Bioproducts Production by a Brazilian Dunaliella salina Isolate Using a High Photon Flux Density Strategy

open access: yesBiotechnology and Applied Biochemistry, EarlyView.
ABSTRACT Dunaliella species are among the most significant biological sources of carotenoids, notably beta‐carotene. Given that chemical synthesis offers a more cost‐effective alternative to biotechnological cultivation, optimizing production strategies is essential for economic viability.
Camylle Guimarães Scheliga   +3 more
wiley   +1 more source

Bioeconomy, sustainability, and digital technologies in Haematococcus lacustris biomass and astaxanthin production: advances and outlook

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Astaxanthin is a carotenoid with strong antioxidant properties, used in research on cancer treatment, ocular injuries, and neurological disorders. When produced by the microalgae Haematococcus lacustris, its antioxidant potential is even higher than that of the synthetic molecule, making it particularly attractive for pharmaceutical and ...
Renata Kühl Rocha   +5 more
wiley   +1 more source

Valorization of bark extracts from Cerrado and Amazon species: phenolic characterization, antioxidant capacity, and photoprotective potential for circular bioeconomy applications

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract Tree bark remains an underexploited source of high‐value‐added phenolic compounds with potential circular bioeconomy applications. This work characterized bark extracts from two species of distinct Brazilian biomes, Stryphnodendron adstringens (Cerrado) and Myrcia eximia (Amazon), obtained with three solvents (ethanol, methanol and acetone ...
Mário Sérgio Lorenço   +7 more
wiley   +1 more source

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy